文献速递认知障碍与痴呆

抗病毒治疗与慢性丙型肝炎患者帕金森病风险的相关性

Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection.
PubMed 文献 · JAMA Neurol · 2019-01-01

5年随访时风险显著降低(HR 0.75),至随访结束获益持续增加(HR 0.71)。

要点

  • 接受以干扰素为基础抗病毒治疗的慢性HCV患者,帕金森病发生风险低于未治疗者。
  • 匹配后治疗组PD发生率密度1.00/1000人年,未治疗组1.39/1000人年。
  • 5年随访时HR 0.75(95%CI 0.59-0.96),随访结束HR 0.71(95%CI 0.58-0.87)。

核心结论

  • 慢性HCV感染患者接受以干扰素为基础的抗病毒治疗后,帕金森病发生率低于未治疗者。
  • 该结果可能支持HCV是帕金森病危险因素的假说。

研究设计与样本

  • 采用台湾全民健康保险研究数据库的理赔数据开展队列研究。
  • 按是否接受抗病毒治疗分为治疗组与未治疗组,并行倾向评分匹配。

主要发现

  • 治疗组帕金森病发生率密度为1.00/1000人年(95%CI 0.85-1.15)。
  • 未治疗组帕金森病发生率密度为1.39/1000人年(95%CI 1.21-1.57)。
  • 5年随访时抗病毒治疗优势达统计学显著(HR 0.75,95%CI 0.59-0.96)。
  • 至随访结束时获益持续增加(HR 0.71,95%CI 0.58-0.87)。

关键数值与推荐

  • 采用Cox比例风险回归模型比较帕金森病风险,计算指数日后1年、3年、5年及队列结束时的HR。

临床怎么用

  • 对慢性HCV感染患者评估帕金森病风险时,可考虑其是否接受过抗病毒治疗。
  • 抗病毒治疗对帕金森病发生的潜在获益在5年随访后更明显,长期随访有意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Epidemiologic evidence suggests that hepatitis C virus (HCV) could be a risk factor for Parkinson disease (PD), but treatment for HCV infection has never been considered in these studies; hence, the association between antiviral therapy and PD incidence has remained unclear. Understanding this association may help in developing strategies to reduce PD occurrence. OBJECTIVE: To identify the risk of PD development in patients with HCV infection receiving antiviral treatment and in patients not receiving this treatment. DESIGN, SETTING, AND PARTICIPANTS: This cohort study obtained claims data from the Taiwan National Health Insurance Research Database. Adult patients with a new HCV diagnosis with or without hepatitis per International Classification of Diseases, Ninth Revision, Clinical Modification codes and anti-PD medications from January 1, 2003, to December 31, 2013, were selected for inclusion. After excluding participants not eligible for analysis, the remaining patients (n = 188 152) were categorized into treated and untreated groups according to whether they received antiviral therapy. Propensity score matching was performed to balance the covariates across groups for comparison of main outcomes. This study was conducted from July 1, 2017, to December 31, 2017. MAIN OUTCOMES AND MEASURES: Development of PD was the main outcome. A Cox proportional hazards regression model was used to compare the risk of PD, and the hazard ratio (HR) was calculated at 1 year, 3 years, and 5 years after the index date and at the end of the cohort. RESULTS: A total of 188 152 patients were included in the analysis. An equal number (n = 39 936) and comparable characteristics of participants were retained in the treated group (with 17 970 female [45.0%] and a mean [SD] age of 52.8 [11.4] years) and untreated group (with 17 725 female [44.4%] and a mean [SD] age of 52.5 [12.9] years) after matching. The incidence density of PD was 1.00 (95% CI, 0.85-1.15) in the treated group and 1.39 (95% CI, 1.21-1.57) per 1000 person-years in the untreated group. The advantage of antiviral therapy reached statistical significance at the 5-year follow-up (HR, 0.75; 95% CI, 0.59-0.96), and this advantage continued to increase until the end of follow-up (HR, 0.71; 95% CI, 0.58-0.87). CONCLUSIONS AND RELEVANCE: Evidence suggested that the PD incidence was lower in patients with chronic HCV infection who received interferon-based antiviral therapy; this finding may support the hypothesis that HCV could be a risk factor for PD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Lin WY, Lin MS, Weng YH, et al. Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection. JAMA Neurol. 2019. PMID: 31168563. doi:10.1001/jamaneurol.2019.1368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。